The Board of Managers elected James C. Powers as Chairman and interim Chief Executive Officer in August 2008 and he became full-time CEO in February 2009. Prior to joining HemoShear, Mr. Powers spent 20 years as an executive in the pharmaceutical R&D services sector. He spent 18 years in executive management at PRA International, a global clinical research organization serving pharmaceutical, biotechnology, and medical device companies. He oversaw PRA’s growth from a niche data-management-services provider to a full-service clinical trials management organization, and expanded its operations and customer base from being U.S.-centric to becoming global. Mr. Powers launched PRA’s oncology therapeutic focus, a market in which PRA continues to be a leader, and he was instrumental in strategic planning and eight acquisitions. During his tenure, the company grew from annual sales of less than $1 million to more than $450 million and from a few employees to a global work force of more than 3,000. He was recently a board member of CellzDirect, Inc., a leading provider of drug metabolism and hepatotoxicity testing products and services, which was acquired by Invitrogen. He was also a board member of Averion International, an international contract clinical research organization. He was an adviser to Tall Oaks Capital and the Coulter Translational Research Partnership in Biomedical Engineering at the University of Virginia. Mr. Powers received a BS in Administration and Management Science from Carnegie-Mellon University.

Dr. Campbell has been an entrepreneur and an economic consultant throughout his 40-year business career. He began in 1968 with an aviation consulting firm in New York and was promoted to Vice President in charge of the firm's Washington office in 1973 . In 1977, he was co-founder of Midway Airlines, Inc., the first new, scheduled start-up carrier after airline deregulation. At Midway, he served as CFO and participated in the raising of venture capital to fund Midway's start-up. He returned to the aviation consulting business in 1983 and has been founder and co-founder of two specialized consulting firms. He is currently Chairman of The Campbell-Hill Aviation Group, headquartered in Alexandria, VA. Throughout his consulting career, he has assisted numerous start-up companies with business plan preparation, financial forecasting, detailed market analyses, and strategic planning studies. Currently he serves as Vice Chairman, investor, and acting CFO of Dynamic Literacy, LLC; advisor to Targeson, LLC, a University of Virginia (UVa)-based biotechnology company; advisor and investor in BioMotion Analytics, LLC; is a member of the advisory board of UVa's Heart and Vascular Center, and of the UVa Patent Foundation Advisory Panel. He earned a Bachelor of Commerce from McGill University, an MBA from the University of Western Ontario, and a PhD in Business Administration from Columbia University.

Dr. Blackman is co-inventor of the HemoShear technology and co-founder of HemoShear. He is a tenured Associate Professor in the Department of Biomedical Engineering at the University of Virginia (UVa). Since August 2002, Dr. Blackman has led an NIH-funded research program investigating the role of the hemodynamic environment in regulating vascular endothelial cell biology in atherosclerosis. Prior to joining UVa, Dr. Blackman spent more than three years training as a postdoctoral research fellow in the Vascular Research Division of Brigham & Women's Hospital and Harvard Medical School. There he developed the first cell-culture-based model to simulate human hemodynamic flow patterns on isolated human endothelial cells, which laid the foundation for current research identifying the importance of precise hemodynamic conditions for regulating arterial vascular biology. Dr. Blackman has published more than 17 peer-reviewed articles, serves on UVa's School of Engineering and Sciences Dean's Research Advisory Committee, is a member of the Robert M. Berne Cardiovascular Research Center, is a peer reviewer for more than 12 scientific journals, and is a standing member of the American Heart Association Bioengineering & Biotechnology study section. Dr. Blackman obtained a BS in Mechanical Engineering from Drexel University and a PhD in Bioengineering from the University of Pennsylvania.

For a list of publications by Brett R. Blackman, Ph.D., go to http://www.ncbi.nlm.nih.gov/pubmed?term=blackman%20br.

Dr. Wamhoff is co-inventor of the HemoShear technology and co-founder of HemoShear. He is an Associate Professor at the University of Virginia (UVa) and leads an NIH-funded laboratory that studies vascular disease at the Cardiovascular Division of UVa’s Department of Medicine. Dr. Wamhoff began his fellowship at UVa to develop rodent models to investigate the molecular mechanisms of genes underlying vascular disease. During this time, he was also employed by Setagon, Inc., a Charlottesville start-up, as lead scientist to develop a novel drug-eluting stent for the treatment of blood vessel stenosis in humans. While at UVa, he has obtained several million dollars in funding from Pfizer, the American Heart Association, NIH, and other organizations to study the fundamental mechanisms that regulate smooth muscle cell phenotypic switching in vascular disease.

Dr. Wamhoff obtained a BS in Biology with a minor in Business Administration from Rhodes College and obtained his PhD from the University of Missouri, where he developed swine models of diabetes and atherosclerosis. Dr. Wamhoff has filed more than 15 patents related to regulation of smooth muscle cell phenotypic switching in vascular disease, leading to licensing of the technology in 2007 to a major device company. He has authored or coauthored 42 publications, three book chapters, and four commentaries. Dr. Wamhoff serves as peer reviewer for more than 15 major scientific journals and is a grant reviewer for the American Heart Association. He has been the recipient of multiple awards, including the Robert M. Berne Trainee Achievement Award, the American Physiological Society Young Cardiovascular Investigator Award, the 2008 Atherosclerosis, Thrombosis, and Vascular Biology (ATVB) Irvine Paige Award, and the 2010 American Physiological Society New Investigator Award for Cardiovascular Research. Dr. Wamhoff devotes philanthropic time to the community by promoting health awareness for the American Heart Association.

For a list of publications by Brian R. Wamhoff, Ph.D., go to http://www.ncbi.nlm.nih.gov/pubmed?term=wamhoff%20br.

Dr. Dash joined HemoShear from the Massachusetts Institute of Technology (MIT) where he had over nine years of experience working on the development and applications of organotypic cell-based liver systems. Prior to joining MIT in 2001, Dr. Dash worked at Pfizer and Parke-Davis in Mumbai, India. Dr. Dash received his Ph.D. in Molecular Toxicology from MIT in 2007 and his M.D. (Residency equivalent) in Pharmacology from King Edward Memorial Hospital in Mumbai, India in 2000. He also received his M.B.B.S. (U.S. Medical Doctor equivalent) in 1995 from S.C.B. Medical College in Cuttack, India.

For a list of publications by Ajit Dash, M.D., Ph.D., go to http://www.ncbi.nlm.nih.gov/pubmed?term=ajit%20dash.

Dr. Hastings obtained her Ph.D. from the Department of Biomedical Engineering at the University of Virginia. Her research focused on elucidating mechanisms of cross-talk and phenotypic modulation of endothelial and smooth muscle cells during initiating stages of atherosclerosis. While developing HemoShear's technology, she has characterized and validated a novel in vitro-based human endothelial and smooth muscle co-culture model whereby hemodynamic shear stress patterns derived from atherosclerosis-prone or atherosclerosis-protective regions are applied to the endothelium. From this model, she identified that the endothelial cell secreted factor Interleukin-8 is released at higher levels during atheroprone flow, and examined its role in modulating the smooth muscle cell inflammatory phenotype, a critical and unexplored feature of the disease.

Dr. Hastings is first author on two peer-reviewed publications, is co-author on five additional high-impact publications, and has presented at international meetings. Prior to obtaining her Ph.D. at UVa, she obtained a bachelor's degree in Biomedical Engineering from North Carolina State University.

For a list of publications by Nicole Hastings, Ph.D., go to http://www.ncbi.nlm.nih.gov/pubmed?term=hastings%20ne.

Mr. Orange is a consultant to HemoShear, where he is responsible for all IT, facilities, and equipment-related purchases and functions. He has spent the past 15 years in various executive management, entrepreneurial, and business consultant roles. Mr. Orange began in 1993 as founder of HSM Inc., a mid-line retail business. He solely raised $1.5 million equity to fund the company's start, and eventually sold the company's technology. In 1996, Mr. Orange went to work as a Sr. Consultant for KPMG LLC focusing on organizational development, change management, operational infrastructure (automated IT design and development), and ERP implementations. Mr. Orange was quickly promoted to Executive Manager and later assisted KPMG with creating their first national eLearning Practice and building out the Cisco/Oracle partnership that included ten, 100M broadband testing centers. He managed teams for major federal contracts including: NASA, DOJ, FBI, DOE, DOD, NSA, NSF and the FAA. In 2001, Mr. Orange left KPMG/BearingPoint to head up an eLearning Practice as an Executive Manager with Arthur Andersen, where he successfully managed contracts with NIH, FDA, TSA, CDC, FAA, DOEd, FBI, and the Executive Offices of the White House. During this period Mr. Orange designed, developed, and implemented many web-based processes to streamline operational processes and reporting, one of which won the FDA the 2001 eGov Award. Mr. Orange joined the University of Virginia in 2002 and currently serves as the Chief Operating Officer for the Robert M. Berne Cardiovascular Research Center, where he manages 16 research laboratories occupying 30,000 sq ft and that employs over 150 staff. Mr. Orange provides management and oversight for over $12 million annually in research support, as well as endowments and investments in excess of $10 million. Mr. Orange received a B.S. in Interdisciplinary Studies from Radford University.

Ms. Yarno has over 26 years experience in the pharmaceutical industry with Johnson & Johnson and Merck & Co., Inc. Prior to joining HemoShear, she was the Chief Marketing Officer at Merck & Co., Inc., where she was responsible for building global marketing and medical support capabilities for the company. Other positions she held while at Merck, included General Manager of the Cardiovascular/Metabolic U.S. Business Unit, Executive Vice President of Worldwide Human Health Marketing, Vice President of Worldwide Cholesterol Reducers Human Health Marketing, and Vice President of the Hypertension and Heart Failure Therapeutic Business Group. Her Merck responsibilities encompassed P&L and global marketing, sales, and business strategies across over 20 therapeutic areas. At Johnson & Johnson's Ortho-McNeil Pharmaceutical division, she was Vice President, Women's Health Care Franchise, which was J&J's highest-producing product line; during her tenure there, the group launched the first direct-to-consumer TV campaign for an oral contraceptive. She is currently on the Board of Directors of St. Jude Medical, a medical device company headquartered in Minneapolis, MN; ADial Pharmaceuticals, and PluroGen Therapeutics, both in Charlottesville, VA. Ms. Yarno is also on the Board of Advisors of OpenQ, Audax Health Solutions, the University of Virginia Patent Foundation and the University of Virginia Heart and Vascular Center. Ms. Yarno has an MBA from Temple University in Philadelphia, PA, and a BS in Marketing from Portland State University in Portland, OR.